Reported Sunday, Nanobiotix CONVERGE Phase 2 Data Shows JNJ-1900 Achieves 100% Disease Control Rate In Stage 3 Inoperable NSCLC Patients

Benzinga Newsdesk www.benzinga.com Positive 95.2%